Laila Almeida Viana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laila Almeida Viana has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Daniel Wagner Santos
Hospital do Rim, Fundação Oswaldo Ramos, São Paulo, Brazil
2 shared publicationsHelio Tedesco-Silva
Hospital do Rim, Fundação Oswaldo Ramos, São Paulo, Brazil
2 shared publicationsMarcus Taver Costa Dantas
Hospital do Rim, Fundação Oswaldo Ramos, São Paulo, Brazil
2 shared publicationsMarina Pontello Cristelli
Hospital do Rim, Fundação Oswaldo Ramos, São Paulo, Brazil
2 shared publications- Alexandra Nicolau Ferreira
Nephrology Division, Hospital do Rim, Fundação Oswaldo Ramos, São Paulo, Brazil
1 shared publication - Ana Raquel Fernandes
Serviço de Nefrologia do Centro Hospitalar de Setúbal, Setúbal, Portugal.
1 shared publication
Latest Publications
- Open Access
- 28 May 2024
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 10 (6) , e1651
Multiple-target Therapy for Posttransplant Focal Segmental Glomerulosclerosis
Background. There is no consensus on the ideal strategy to treat posttransplant focal segmental glomerulosclerosis. The multiple-target therapy, which consisted of high-dose intravenous cyclosporine, prednisone, and plasmapheresis, showed favorable results. Methods. This single-center, prospective study sought to evaluate the multiple-target therapy in an independent cohort of patients. Results. Thirteen patients with posttransplant focal segmental glomerulosclerosis received multiple-target therapy. Complete remission was achieved in 2 patients (15.4%), and partial remission in another 2 patients (15.4%). Four patients (30.7%) did not show remission, and 5 patients (38%) lost the graft because of posttransplant focal segmental glomerulosclerosis during the 12-mo follow-up. Premature discontinuation of treatment occurred in 10 patients (77%), all associated with infectious adverse events. Cytomegalovirus was the most common complication, and preemptive therapy was used instead of prophylaxis. Conclusions. In this cohort of patients, the efficacy of the multiple-target therapy was poor and limited by the high incidence of infectious adverse events. Export
- 28 May 2024
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 10 (6) , e1651
Open AccessMultiple-target Therapy for Posttransplant Focal Segmental Glomerulosclerosis
Background. There is no consensus on the ideal strategy to treat posttransplant focal segmental glomerulosclerosis. The multiple-target therapy, which consisted of high-dose intravenous cyclosporine, prednisone, and plasmapheresis, showed favorable results. Methods. This single-center, prospective study sought to evaluate the multiple-target therapy in an independent cohort of patients. Results. Thirteen patients with posttransplant focal segmental glomerulosclerosis received multiple-target therapy. Complete remission was achieved in 2 patients (15.4%), and partial remission in another 2 patients (15.4%). Four patients (30.7%) did not show remission, and 5 patients (38%) lost the graft because of posttransplant focal segmental glomerulosclerosis during the 12-mo follow-up. Premature discontinuation of treatment occurred in 10 patients (77%), all associated with infectious adverse events. Cytomegalovirus was the most common complication, and preemptive therapy was used instead of prophylaxis. Conclusions. In this cohort of patients, the efficacy of the multiple-target therapy was poor and limited by the high incidence of infectious adverse events. Export
- 20 July 2023
- Published by Wolters Kluwer Health in Transplantation
- Vol. 107 (8) , 1835-1845
Conversion to mTOR Inhibitor to Reduce the Incidence of Cytomegalovirus Recurrence in Kidney Transplant Recipients Receiving Preemptive Treatment: A Prospective, Randomized Trial
Background.: Although mammalian target of rapamycin inhibitors (mTORi) are associated with a lower incidence of the first episode of cytomegalovirus (CMV) infection/disease in kidney transplant recipients receiving calcineurin inhibitors (CNIs), the efficacy and safety of the conversion from the antimetabolite to an mTORi for the prevention of CMV recurrence are unknown. Methods.: In this single-center prospective randomized trial, low-immunological-risk, CMV-positive kidney transplant recipients receiving preemptive therapy were randomized to be converted (sirolimus [SRL]) or not (control [CTR]) immediately after the treatment of the first episode of CMV infection/disease and were followed for 12 mo. A sample size of 72 patients was calculated to demonstrate a 75% reduction in the incidence of CMV recurrence (80% power, 95% confidence level). Results.: Of 3247 adult kidney transplants performed between September 13, 2015, and May 7, 2019, 1309 (40%) were treated for the first CMV infection/disease, and 72 were randomized (35 SRL and 37 CTR). In the SRL group, there were no episodes of CMV recurrence, compared with 16 patients in the CTR group (0% versus 43%; P < 0.0001). Four patients had a second and 1 a third recurrent CMV event. Three of them were converted to SRL and did not develop any further CMV events. There were no differences in the incidence of acute rejection, drug discontinuation, kidney function, and patient and graft survival at 12 mo. Conclusions.: These data suggest that, in CMV-positive kidney transplant recipients, the conversion from an antiproliferative drug to SRL after the first CMV episode is an effective and safe strategy for recurrent episodes.
- 20 July 2023
- Published by Wolters Kluwer Health in Transplantation
- Vol. 107 (8) , 1835-1845
Conversion to mTOR Inhibitor to Reduce the Incidence of Cytomegalovirus Recurrence in Kidney Transplant Recipients Receiving Preemptive Treatment: A Prospective, Randomized Trial
Background.: Although mammalian target of rapamycin inhibitors (mTORi) are associated with a lower incidence of the first episode of cytomegalovirus (CMV) infection/disease in kidney transplant recipients receiving calcineurin inhibitors (CNIs), the efficacy and safety of the conversion from the antimetabolite to an mTORi for the prevention of CMV recurrence are unknown. Methods.: In this single-center prospective randomized trial, low-immunological-risk, CMV-positive kidney transplant recipients receiving preemptive therapy were randomized to be converted (sirolimus [SRL]) or not (control [CTR]) immediately after the treatment of the first episode of CMV infection/disease and were followed for 12 mo. A sample size of 72 patients was calculated to demonstrate a 75% reduction in the incidence of CMV recurrence (80% power, 95% confidence level). Results.: Of 3247 adult kidney transplants performed between September 13, 2015, and May 7, 2019, 1309 (40%) were treated for the first CMV infection/disease, and 72 were randomized (35 SRL and 37 CTR). In the SRL group, there were no episodes of CMV recurrence, compared with 16 patients in the CTR group (0% versus 43%; P < 0.0001). Four patients had a second and 1 a third recurrent CMV event. Three of them were converted to SRL and did not develop any further CMV events. There were no differences in the incidence of acute rejection, drug discontinuation, kidney function, and patient and graft survival at 12 mo. Conclusions.: These data suggest that, in CMV-positive kidney transplant recipients, the conversion from an antiproliferative drug to SRL after the first CMV episode is an effective and safe strategy for recurrent episodes.
- 24 December 2020
- Published by Wolters Kluwer Health in Transplantation
- Vol. 105 (1) , e1-e3
Kidney Transplantation in Patients With SARS-CoV-2 Infection: A Case Series Report
- 24 December 2020
- Published by Wolters Kluwer Health in Transplantation
- Vol. 105 (1) , e1-e3
Kidney Transplantation in Patients With SARS-CoV-2 Infection: A Case Series Report
- Open Access
- 17 December 2018
- Published by Elsevier in American Journal of Transplantation
- Vol. 19 (5) , 1421-1431
Influence of epidemiology, immunosuppressive regimens, clinical presentation, and treatment on kidney transplant outcomes of patients diagnosed with tuberculosis: A retrospective cohort analysis
- 17 December 2018
- Published by Elsevier in American Journal of Transplantation
- Vol. 19 (5) , 1421-1431
Open AccessInfluence of epidemiology, immunosuppressive regimens, clinical presentation, and treatment on kidney transplant outcomes of patients diagnosed with tuberculosis: A retrospective cohort analysis
- 1 July 2016
- Published by Elsevier in Pregnancy Hypertension
- Vol. 6 (3) , 232
109 Pregnancy among kidney transplanted women: Feasibility of pregnancy and effects on the mother and renal graft
- 1 July 2016
- Published by Elsevier in Pregnancy Hypertension
- Vol. 6 (3) , 232
109 Pregnancy among kidney transplanted women: Feasibility of pregnancy and effects on the mother and renal graft